Search for Clinical Trial Results

Sponsored By

Angioimmunoblastic Lymphadenopathy With Dysproteinemia - 29 Studies Found

Status Study
Completed Study Name: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition:
  • Angioimmunoblastic T-cell Lymphoma
  • Extranodal Marginal Zone B-c
    Date: 2000-11-06
    Interventions: Drug: oxaliplatin Given IV Other Names:
Terminated Study Name: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Condition:
  • Angioimmunoblastic T-cell Lymphoma
  • Extranodal Marginal Zone B-c
    Date: 2000-07-05
    Interventions: Drug: nelarabine Given IV Other Names:
Completed Study Name: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Condition:
  • Peripheral T-cell Lymphoma (Not Otherwise Specified)
  • Angioimmunoblasti
    Date: 2009-05-11
    Interventions: Drug: panobinostat and bortezomib oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.
Completed Study Name: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Condition:
  • T-cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma
  • Date: 2015-10-26
    Interventions: Drug: Brentuximab vedotin study drug given intravenously to determine efficacy in study diseases
Completed Study Name: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Condition:
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma Date: 2006-02-16
    Interventions:
    • Drug: gemcitabine hydrochloride

Completed Study Name: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Condition:
  • Adult T-Cell Leukemia/Lymphoma
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • Drug: Brentuximab Vedotin Give
Terminated Study Name: Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Condition:
  • Lymphoma
  • Lymphoproliferative Disorder

Date: 2004-10-06
Interventions: Drug: bortezomib + ganciclovir Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. P
Completed Study Name: Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Date: 2002-06-06
Interventions:
  • Drug: cyclophosphamide
  • Drug: prednisone
Completed Study Name: Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
Condition:
  • Gastric Cancer
  • Head and Neck Cancer
  • Lymphoma
  • Date: 2010-06-18
    Interventions:
    • Biological: EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant mo
<<< Previous